TCIM
CHRS icon

TIAA CREF Investment Management’s Coherus Oncology CHRS Stock Holding History

TIAA CREF Investment Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$28.4M Buy
2,083,163
+910,610
+78% +$12.1M 0.02% 574
2018
Q4 		$10.6M Buy
1,172,553
+4,797
+0.4% +$55.5K 0.01% 925
2018
Q3 		$19.3M Buy
1,167,756
+29,474
+3% +$522K 0.01% 754
2018
Q2 		$15.9M Buy
1,138,282
+71,392
+7% +$1.02M 0.01% 870
2018
Q1 		$11.8M Buy
1,066,890
+23,895
+2% +$261K 0.01% 1026
2017
Q4 		$9.18M Buy
1,042,995
+12,313
+1% +$132K 0.01% 1194
2017
Q3 		$13.8M Buy
1,030,682
+29,578
+3% +$391K 0.01% 953
2017
Q2 		$14.4M Buy
1,001,104
+414,229
+71% +$7.97M 0.01% 920
2017
Q1 		$12.4M Buy
586,875
+308,332
+111% +$7.58M 0.01% 985
2016
Q4 		$7.84M Sell
278,543
-185,371
-40% -$5.19M 0.01% 1292
2016
Q3 		$12.4K Sell
463,914
-261,208
-36% -$7.13M 0.01% 992
2016
Q2 		$12.2M Buy
725,122
+5,669
+0.8% +$106K 0.01% 950
2016
Q1 		$15.3M Sell
719,453
-19,646
-3% -$322K 0.01% 847
2015
Q4 		$17M Sell
739,099
-18,780
-2% -$483K 0.01% 820
2015
Q3 		$15.2M Sell
757,879
-1,335
-0.2% -$40.6K 0.01% 843
2015
Q2 		$21.9M Buy
759,214
+703,096
+1,253% +$17.8M 0.02% 755
2015
Q1 		$1.72M Buy
56,118
+54,595
+3,585% +$1.41M ﹤0.01% 2318
2014
Q4 		$25K Buy
+1,523
New +$21.5K ﹤0.01% 3136

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TIAA CREF Investment Management's CHRS Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Coherus Oncology (CHRS) stake by 78% in Q1 2019, buying an estimated $12.1M and bringing the position to 2,083,163 shares worth $28.4M. The position accounts for 0.02% of the portfolio, ranked #574.

TIAA CREF Investment Management first reported a position in CHRS in Q4 2014 and has held it in 18 quarters since. 117 funds tracked by Wall St. Rank hold CHRS as of Q1 2019.

  • TIAA CREF Investment Management held 2,083,163 shares of Coherus Oncology worth $28.4M as of Q1 2019.
  • TIAA CREF Investment Management bought 910,610 Coherus Oncology shares in Q1 2019, an estimated $12.1M.
  • Coherus Oncology made up 0.02% of TIAA CREF Investment Management's portfolio in Q1 2019, its #574 holding.
  • TIAA CREF Investment Management first reported a position in Coherus Oncology in Q4 2014 and has held it in 18 quarters since.
  • 117 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.